We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 92.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2007 16:15 | so far its just MMS marking it down - not many sells at all but will wait for delayed trades before conclusions are made. MM | money mad | |
24/4/2007 16:14 | if anyone is still interested,take five minutes and look over there web site. find out for yourself,dyor etc etc. p.s. i do hold these shares. | mr mat | |
24/4/2007 16:13 | jarvisd why? | money mad | |
24/4/2007 16:12 | Just tripled my holding.....seems very oversold. P | patricktrfc | |
24/4/2007 16:12 | zzzzzzzzzzzzzzzzzzzz should/will fall further on wed. | jarvisd4e | |
24/4/2007 16:10 | anyone else any views or am i here alone | money mad | |
24/4/2007 16:05 | and all the director buying i forgot to mention - must have more up there sleeve | money mad | |
24/4/2007 16:02 | How big was huntingdons disease for this treatment - Miraxion is not just in trial for Huntingdons disease - but for other CNS disorders Amarin's core development pipeline includes Miraxion for CNS disorders, an oral formulation of apomorphine for treating patients with advanced Parkinson's disease, a nasal formulation of lorazepam for treating emergency seizures and our proprietary pre-clinical combinatorial lipid program. Seems oversold - well not that there seems to be many visible sellers MM | money mad | |
24/4/2007 15:49 | Will be no serious buying until it's more stable, Winterflood et al don't appear know what to do with the share price this afternoon. Q | quidzinn | |
24/4/2007 15:49 | L2 1v2 for anyone who cares 1k v 6k | bozzy_s | |
24/4/2007 15:37 | Thanks for the update moneymad, know nothing about this, just a 75% drop is bound to bring a DCB soon, but it looks like this one has been overdone anyway as they have other pipeline products. The big cheese from Pfizer would not join them on the back of a single drug? Reckon we may see 60/70 tomorrow. P | patricktrfc | |
24/4/2007 15:34 | its all over the shop - quidzinn - what d o you think about its other products? Dont you think this sell off has been overdone? | money mad | |
24/4/2007 15:29 | Bid/offer both @48p but no auction ??? Q | quidzinn | |
24/4/2007 15:29 | LONDON (AFX) - Amarin Corporation PLC said that, following an agreement with Elan Corp, it has acquired a global license to develop and market a new form of epilepsy treatment using a formulation patented by Elan. Amarin said it believes the nasal lorazepam formulation, intended to treat emergency seizures in epilepsy outpatients, could have annual sales of up to 300 mln usd in the US, partly because it would be more convenient to administer than the sole treatment currently approved for outpatients by the US Food and Drug Administration, Diazepam rectal gel. | money mad | |
24/4/2007 15:29 | LONDON (AFX) - Amarin Corporation PLC said that, following an agreement with Elan Corp, it has acquired a global license to develop and market a new form of epilepsy treatment using a formulation patented by Elan. Amarin said it believes the nasal lorazepam formulation, intended to treat emergency seizures in epilepsy outpatients, could have annual sales of up to 300 mln usd in the US, partly because it would be more convenient to administer than the sole treatment currently approved for outpatients by the US Food and Drug Administration, Diazepam rectal gel. | money mad | |
24/4/2007 15:28 | We expanded Amarin's development pipeline with the acquisition of global rights to a novel oral formulation of apomorphine and made significant progress on its development during the year | money mad | |
24/4/2007 15:26 | this isnt its only product have a read through its history | money mad | |
24/4/2007 15:21 | 20p and i might consider it! | danski | |
24/4/2007 15:20 | Will pick some up at 20p - not before! | double6 | |
24/4/2007 15:19 | too risky for me. good luck to anyone trying to bottomfish. if the analysts/press get bearish tomorrow, it could get caned further. if they start talking up the other stuff, then you'll make your money quickly... | danski | |
24/4/2007 15:15 | MMs still messing around with share price - will take a while until the dust settles - always going to be a risky punt though. Q | quidzinn | |
24/4/2007 14:56 | In at 44, 75%+ down on the day and downside limited to 17p cash in bank. Will be back out at 66, easy 50% within a week or so. Risky punt, but have made nicely on Imperial Energy so this is a freebie for me. Best of luck to all P | patricktrfc | |
24/4/2007 14:49 | this was clearly their headline act - they do mention others in dispatches - but if so much store was placed on just this one drug, then it was a highly speculative venture indeed, even by the standards of the biotech sector. | danski | |
24/4/2007 14:35 | What confidence is there now in other pipeline products? They may as well be drilling for oil Q | quidzinn |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions